300 North Capital’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

300 North Capital’s Portfolio SLXP Stock Details SLXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-30,129	Closed	-$3.46M	–	134
2014 Q4	$3.46M	Buy	30,129 +9,377	+45%	+$1.14M	0.8%	58
2014 Q3	$3.24M	Buy	+20,752	New	+$3.01M	0.86%	49

Other funds holding SLXP

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

YCMGA

York Capital Management Global Advisors New York $87.8M AUM 45.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

300 North Capital's SLXP Position: Q1 2015 in Review

300 North Capital sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q1 2015, closing a stake of 30,129 shares — an estimated $3.46M sold.

300 North Capital first reported a position in SLXP in Q3 2014 and held it in 2 quarters. The position peaked at $3.46M in Q4 2014. 298 funds tracked by Wall St. Rank hold SLXP as of Q1 2015.

300 North Capital reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q1 2015 after selling out during the quarter.
300 North Capital sold 30,129 SALIX PHARMACEUTICALS LTD DEL shares in Q1 2015, an estimated $3.46M.
300 North Capital first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q3 2014 and held it in 2 quarters.
300 North Capital's SALIX PHARMACEUTICALS LTD DEL position peaked at $3.46M in Q4 2014.
298 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q1 2015.

Based on 300 North Capital's 13F filing for Q1 2015, filed 8 May 2015.